German family-owned drugmaker Grünenthal has appointed Mark Fladrich to the position of chief commercial officer (CCO) responsible for the firm’s entire global commercial organization. 9 May 2017
Cambridge, UK-based monoclonal antibody specialist Kymab Group today announced the appointment of Dr Sonia Quaratino as its first chief medical officer. Dr Quaratino will manage the clinical development of the group's expanding therapeutic antibody portfolio. 9 May 2017
US biotech Seattle Genetics has agreed to terminate its license agreement with Immunomedics for cancer drug candidate sacituzumab govitecan (IMMU-132) and settle the related litigation. 8 May 2017
Paris, France-based GenSight Biologics has appointed Mohamed Genead, the former head of ophthalmology/retina gene therapy at Biogen, as the company’s new chief medical officer. 4 May 2017
Bayer hA appointed Bhavesh Ashar as senior vice president and head of oncology for the company's Pharmaceuticals Division in the USA, reporting to Carsten Brunn, head of Bayer Pharmaceuticals for the Americas region. 3 May 2017
Private company ImCheck Therapeutics has raised 20 million euros ($22 million) to fund research into antibodies involved in the immune system. 3 May 2017
In the midst of a comprehensive cost cutting program rumored to include thousands of job losses, Teva chief financial officer Eyal Desheh is about to quit, Israeli press reports. 3 May 2017
Recently-floated PLx Pharma has made two new executive appointments, hiring Rita O’Connor as chief financial officer and Michael Dillon as vice president of sales and marketing. 3 May 2017
Dr Ellen Donnelly, former head of clinical operations of the neuroscience and pain therapeutic area at Pfizer, has been appointed as chief executive officer at Modus Therapeutics. 24 April 2017
Sweden’s Karolinska Development says that Bo Jesper Hansen, chairman of the company's board, has decided not stand for re-election at the 2017 Annual General Meeting. 20 April 2017
French drugmaker Ipsen on Friday announced the appointment of Dr Alexandre Lebeaut as executive vice-president, R&D, and chief scientific officer, effective immediately. 18 April 2017
Privately-held UK biotech firm Destiny Pharma has appointed Neil Clark as chief executive and member of the board of directors, effective immediately. 13 April 2017
In a finding that might add weight to industry calls for continued free movement of vital talent post-Brexit, a study has shown that country managers and European heads in UK pharma are far more internationally diverse than their French and German counterparts. 12 April 2017
David Hung, the founder and former chief executive of Medivation, an oncology-focused biopharma bought by US pharma giant Pfizer for $14 billion last year, has switched his attention to dementia in his role. 11 April 2017
USA-based Marinus Pharmaceuticals, a biotech company focused on developing treatments for epilepsy and neuropsychiatric disorders, has appointed Lorianne Masuoka as chief medical officer. 11 April 2017
Tim Harris has been appointed as executive vice president of R&D at Bioverativ, a new company focussed on hemophilia and other rare blood disorders. 11 April 2017
French pharma major Sanofi (Euronext: SAN) has promoted Bill Sibold to the post of executive vice president Sanofi Genzyme, effective July 1, 2017. In this role, Mr Sibold will be a member of the executive committee. 5 April 2017
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024